China Biopharmaceutical (01177.HK): TQC3721 Inhalation Suspension "PDE3/4 Inhibitor" Phase III Registration Clinical Trial Completes Enrollment of All Subjects

Zhito Finance APP news, China Biopharmaceutical (01177.HK) announced that the key registrational Phase III clinical trial (PACER-III) of TQC3721 inhalation suspension "PDE3/4 inhibitor", a National Class 1 innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), a subsidiary of the Group, for maintenance treatment of chronic obstructive pulmonary disease (COPD), has recently completed enrollment of all subjects.